

Amylin Pharmaceuticals Incorporated

[View the current Amylin Pharmaceuticals Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocomplete/747-Amylin+Pharmaceuticals+Incorporated.html)

(<http://www.bioportfolio.com/biocomplete/747-Amylin+Pharmaceuticals+Incorporated.html>)

Contact Details:

9373 Towne Centre Drive
San Diego

Tel: 619 552 2200
Fax: 619 552 2212
Email:

92121
United States of America

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. The company was founded in 1987 on the discovery of a hormone, amylin, produced by the same beta cells of the pancreas that make insulin. Since then, Amylin has built a strong foundation on research and development. Amylin's scientists are primarily focused on investigating the potential utility of new peptide hormone candidates. The company has amassed significant research and clinical expertise in metabolic medicine including the areas of diabetes, obesity and cardiovascular disease. By "Challenging Science," Amylin challenges conventional thinking to create innovative approaches to the discovery, development and commercialization of novel therapies for metabolic diseases. Amylin's approach and dedication are rooted in the belief that they will be "Changing Lives" for millions of people - not only with the drugs currently in late-stage development, but also with their pipeline of future therapies.

Recent Publications by Amylin Pharmaceuticals Incorporated:



- [Mechanisms of Amylin/Leptin Synergy in Rodent Models.](#)

*The present studies aimed to identify mechanisms contributing to...*31st October, 2009
Amylin Pharmaceuticals (V.F.T., J.L.T., G.G., C.W., P.S.G., C.V., D.G.P.,- Endocrinology. 2009 Oct 29.
([DOI Direct Link](#))

- [Being supermarket savvy.](#)

*The present studies aimed to identify mechanisms contributing to...*31st October, 2009
Amylin Pharmaceuticals, Inc., Island Park, NY, USA.- Diabetes Self Manag. 2009 Sep-Oct;26(5):57, 59-61, 63.

- [Improving your diabetes care visits.](#)

*The present studies aimed to identify mechanisms contributing to...*26th September, 2009

- Amylin Pharmaceuticals, Inc., Lexington, Kentucky, USA.- Diabetes Self Manag. 2009 Jul-Aug;26(4):23-4, 26-8, 31.
- [Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.](#)
*OBJECTIVE: This study assessed the pharmacokinetics, pharmacodynamics, and...*28th July, 2009
 Amylin Pharmaceuticals, Inc., San Diego, California 92121, USA.- Clin Ther. 2009 Apr;31(4):806-15. ([DOI Direct Link](#))
 - [Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily.](#)
*AIMS: To assess treatment satisfaction and weight-related quality of life...*4th July, 2009
 Amylin Pharmaceuticals Inc., San Diego, CA 92121, USA.- Diabet Med. 2009 Jul;26(7):722-8. ([DOI Direct Link](#))
 - [Interaction of Leptin and Amylin in the Long-term Maintenance of Weight Loss in Diet-induced Obese Rats.](#)
*We have previously shown that combined amylin + leptin agonism elicits...*23rd June, 2009
 Amylin Pharmaceuticals, Inc., San Diego, California, USA.- Obesity (Silver Spring). 2009 Jun 18. ([DOI Direct Link](#))
 - [Peptide-lisinopril conjugates: design, synthesis and biological activities.](#)
*OBJECTIVE: This study assessed the pharmacokinetics, pharmacodynamics, and...*6th June, 2009
 Research Chemistry, Amylin Pharmaceuticals Inc., 9360 Towne Centre Drive,- Adv Exp Med Biol. 2009;611:535-6.
 - [Synthesis & biological evaluation of PYY\(3-36\) analogs substituted with alanine.](#)
*OBJECTIVE: This study assessed the pharmacokinetics, pharmacodynamics, and...*6th June, 2009
 Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA- Adv Exp Med Biol. 2009;611:515-6.
 - [Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications.](#)
*Amylin receptor agonism is emerging as part of an integrated neurohormonal...*16th April, 2009
 Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA.- Arch Neurol. 2009 Mar;66(3):306-10. ([DOI Direct Link](#))
 - [Exenatide improves hypertension in a rat model of the metabolic syndrome.](#)
*BACKGROUND: Exenatide is a peptide incretin mimetic that has...*27th March, 2009
 Amylin Pharmaceuticals Inc., San Diego, California, USA.- Metab Syndr Relat Disord. 2009 Aug;7(4):327-34. ([DOI Direct Link](#))
 - [Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors.](#)
*Type 2 diabetes is a chronic disease characterized by impaired insulin...*14th February, 2009
 Amylin Pharmaceuticals, Inc., 9360 Towne Centre Dr., San Diego, CA 92121,- Curr Diabetes Rev. 2008 May;4(2):101-9.
 - [Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy.](#)
*Contrary to its historical epithet as a lifestyle disorder, obesity is now...*14th February, 2009
 Amylin Pharmaceuticals, Inc. 9360 Towne Centre Drive, San Diego, CA 92121,- Curr Diabetes Rev. 2008 May;4(2):79-91.
 - [Hormone-based therapies in the regulation of fuel metabolism and body weight.](#)
*BACKGROUND: The integrated central actions of hormones secreted from...*4th February, 2009
 Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA- Expert Opin Biol Ther. 2008 Nov;8(11):1733-47. ([DOI Direct Link](#))
 - [Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.](#)
*OBJECTIVE: To characterize the interactive effects of amylin with...*16th January, 2009
 Amylin Pharmaceuticals, Inc, San Diego, CA 92121, USA.- Int J Obes (Lond). 2008 Aug;32(8):1201-10. Epub 2008 Jun 17. ([DOI Direct Link](#))

- [Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms.](#)

Previously, we reported that combination treatment with rat amylin (100...7th January, 2009 Amylin Pharmaceuticals, Inc., San Diego, California 92121, USA.- Endocrinology. 2008 Nov;149(11):5679-87. Epub 2008 Jul 31. ([DOI Direct Link](#))

Press Releases on Amylin Pharmaceuticals Incorporated:

H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics	20th November, 2009	Quest Diagnostics Incorporated	<i>-- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during</i>
Reportlinker Adds Imaging Agents - A Worldwide Market Review	20th November, 2009	Reportlinker	<i>NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Imaging Agents - A Worldwide Market Review http://www.reportlinker.com</i>
AstraZeneca and the Philadelphia Department of Public Health Provide Free Medicines to Pennsylvania's Uninsured	20th November, 2009	AstraZeneca	<i>WILMINGTON, Del., Nov. 20 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and the Philadelphia Department of Public Health announced today at a press conference at Philadelphia Health Care Center #6</i>
Impax Laboratories Drives Stronger Performance with IBM Business Analytics	20th November, 2009	IBM	<i>-- C-level Executive Committee can now easily pull together a single view of net sales, profitability and competitive market share information, helping them to determine whether</i>
New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)	20th November, 2009	Quest Diagnostics Incorporated	<i>MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of employment-related drug testing services,</i>

- [The Mulligan Law Firm is Investigating Injury Claims: Diabetes Drug Byetta Linked to Kidney-Related Side Effects](#)
PRWeb: Nov 15 2009 8:09AM Matching: amylin pharmaceuticals
- [MDRNA, Inc. Announces Third Quarter 2009 Financial Results](#)
Pharmacy Choice: Nov 13 2009 6:25AM Matching: amylin pharmaceuticals
- [Amylin Pharmaceuticals To Present At The 18th Annual Credit Suisse Healthcare Conference; Webcast At 1:00 PM E](#)
RTTNews.com: Nov 11 2009 5:58PM Matching: amylin pharmaceuticals
- [Reuters Summit-Novo CEO hopeful on Victoza approval](#)
Forbes.com: Nov 11 2009 5:24PM Matching: amylin pharmaceuticals
- [Novo CEO hopeful on Victoza approval](#)
Reuters UK: Nov 11 2009 4:56PM Matching: amylin pharmaceuticals
- [Novo CEO hopeful on Victoza approval](#)
Reuters: Nov 11 2009 4:44PM Matching: amylin pharmaceuticals
- [The Mulligan Law Firm is Investigating Injury Claims: Diabetes Drug Byetta Linked to Kidney-Related Side Effects and Acute Renal Failure](#)
Earthtimes.org: Nov 11 2009 10:35AM Matching: amylin pharmaceuticals
- [Amylin Obesity Drug Grabbing the Attention of Analysts, Investors](#)
San Diego Business Journal: Nov 9 2009 5:50PM Matching: amylin pharmaceuticals
- [FDA Issues Warning for Diabetes Drug](#)
Medbroadcast: Nov 8 2009 3:14AM Matching: amylin pharmaceuticals
- [Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference](#)
Pharma Live: Nov 7 2009 1:42AM Matching: amylin pharmaceuticals
- [Pharmaceuticals see proposed health care legislation as mixed bag](#)
San Diego Daily Transcript: Nov 7 2009 3:31AM Matching: amylin pharmaceuticals
- [Byetta Indication Expanded, Labeling Gets New Warning](#)
FDA News: Nov 7 2009 4:49AM Matching: amylin pharmaceuticals
- [Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference](#)
Freshnews.com: Nov 6 2009 3:03AM Matching: amylin pharmaceuticals
- [Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference](#)
Financials.com: Nov 6 2009 5:45AM Matching: amylin pharmaceuticals
- [Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference](#)
KSLA: Nov 6 2009 3:40AM Matching: amylin pharmaceuticals

Amylin Pharmaceuticals Incorporated Clinical Trials:



- [Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes](#)



Amylin Pharmaceuticals Incorporated Patents:

- 6579851- [Effects of glucagon-like peptide-1 \(7-36\) on antro-pyloro-duodenal motility](#)
- 6936584- [Mixed amylin activity compounds](#)
- 6956026- [Use of exendins for the reduction of food intake](#)
- 6982248- [Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue](#)
- 6989366- [Exendins, exendin agonists, and methods for their use](#)
- 6998387- [Human appetite control by glucagon-like peptide receptor binding compounds](#)
- 7056887- [Treatment of acute coronary syndrome with GLP-1](#)
- 7101853- [Method for treating or preventing gastritis using amylin or amylin agonists](#)
- 7105489- [Methods and compositions for treating polycystic ovary syndrome](#)
- 7105490- [Methods and compositions for treating polycystic ovary syndrome](#)
- 7115569- [Exendins, exendin agonists, and methods for their use](#)
- 6924264- [Modified exendins and exendin agonists](#)
- 6902744- [Exendin agonist formulations and methods of administration thereof](#)
- 6894024- [Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide](#)
- 6602694- [Uncoupling protein 4 \(UCP-4\)](#)
- 6608029- [Methods for regulating gastrointestinal motility](#)
- 6610824- [Amylin agonist peptides and uses therefor](#)
- 6703359- [Inotropic and diuretic effects of exendin and GLP-1](#)
- 6706689- [Treatment of acute coronary syndrome with GLP-1](#)
- 6723530- [Polynucleotides encoding proexendin, and methods and uses thereof](#)
- 6852690- [Method and composition for enhanced parenteral nutrition](#)
- 6858576- [Methods for regulating gastrointestinal motility](#)
- 6872700- [Methods for glucagon suppression](#)
- 6884579- [GLP-1 as a diagnostic test to determine .beta.-cell function and the presence of the condition of IGT and type-II diabetes](#)
- 7118737- [Polymer-modified synthetic proteins](#)
- 7129327- [Polypeptide and protein derivatives and process for their preparation](#)
- 7407934- [Methods for regulating postprandial blood glucose](#)
- 7419952- [Use of exendins and agonists thereof to treat diabetes](#)
- 7442680- [Inotropic and diuretic effects of GLP-1 and GLP-1 agonists](#)
- 7452858- [Treatment of gestational diabetes](#)
- 7482425- [Compositions for lipid matrix-assisted chemical ligation](#)
- 7521423- [Exendin pharmaceutical compositions](#)
- 7538182- [Polypeptide and protein derivatives and process for their preparation](#)
- 7563871- [Polymer-based sustained release device](#)
- 7566697- [Carboxy protection strategies for acidic C-terminal amino acids in chemical ligation of oligopeptides](#)
- 7569540- [Method for enhanced parenteral nutrition](#)
- 7407932- [Methods for glucagon suppression using modified exendins](#)
- 7399744- [Methods for affecting body composition](#)
- 7399489- [Exendin analog formulations](#)
- 7138375- [Use of exendins and agonists thereof for lowering plasma lipid](#)
- 7153825- [Methods for glucagon suppression using modified exendins](#)
- 7157555- [Exendin agonist compounds](#)

- 7220721- [Exendin agonist peptides](#)
- 7223725- [Exendin agonist compounds](#)
- 7259136- [Compositions and methods for treating peripheral vascular disease](#)
- 7265087- [Exendin improves .beta.-cell response in subjects with impaired glucose tolerance](#)
- 7271238- [Amylin agonist peptides and uses therefor](#)
- 7297761- [Pharmaceutical compositions containing exendins](#)
- 7312196- [Formulations for amylin agonist peptides](#)
- 7608692- [Exendins and exendin agonists modified with albumin](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

